SAB Biotherapeutics Q3 2026 Results: Net Loss of $22.3M
SAB Biotherapeutics reported a net loss of $22.3 million for the third quarter of 2026, compared to a net income of $45.4 million in the prior year period, primarily due to a significant decrease in the non-cash gain from the change in fair value of warrant liabilities. Operating expenses increased substantially to $25.9 million as the company ramped up research and development activities.
- Key figure
- Net loss $22.3M